Savara Inc (NASDAQ:SVRA) Stake Raised by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its position in Savara Inc (NASDAQ:SVRA) by 14.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 115,604 shares of the company’s stock after purchasing an additional 14,867 shares during the period. Oppenheimer & Co. Inc. owned about 0.07% of Savara worth $490,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SVRA. Victory Capital Management Inc. increased its holdings in shares of Savara by 7.0% during the 3rd quarter. Victory Capital Management Inc. now owns 140,010 shares of the company’s stock valued at $594,000 after acquiring an additional 9,180 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Savara by 95.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 31,658 shares of the company’s stock valued at $134,000 after buying an additional 15,423 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Savara in the 3rd quarter worth approximately $192,000. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Savara in the 2nd quarter worth approximately $215,000. Finally, Nantahala Capital Management LLC lifted its position in shares of Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Savara

In other news, Director Joseph S. Mccracken bought 20,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were purchased at an average price of $2.95 per share, with a total value of $59,000.00. Following the transaction, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.13% of the stock is owned by insiders.

Analysts Set New Price Targets

SVRA has been the subject of several analyst reports. HC Wainwright cut their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Finally, Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Savara has a consensus rating of “Moderate Buy” and an average target price of $10.17.

Savara Stock Up 6.5 %

NASDAQ SVRA opened at $3.13 on Thursday. Savara Inc has a fifty-two week low of $2.82 and a fifty-two week high of $5.70. The stock has a market capitalization of $537.17 million, a PE ratio of -7.23 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The business has a fifty day moving average price of $3.82 and a two-hundred day moving average price of $4.16.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). Equities analysts expect that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.